drugset / Trial / NCT04130061
Human Amniotic Membrane to Decrease Post Operative Atrial Fibrillation
Phase 0
Completed
27 enrolled
University of Utah
National Center for Advancing Translational Sciences (NCATS) · collab
RandomizedParallel-groupOpen-labelPrevention
Summary
This study will evaluate the application of hAM at the time of cardiac surgery to decrease inflammation and the subsequent substrate to reduce incidence of post-operative atrial fibrillation. Patients will randomized 1:1 to receive either hAM application or standard of care.
Timeline
- Start
- 2019-10-11
- Primary completion
- 2021-06-01
- Completion
- 2021-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Human Amniotic Membrane | Unknown | — | Other |